Investigational new drugs

Keyphrases

Publications

2023

Mehmet Ali Karaselek, Serkan Kuccukturk, Tugce Duran, Ahmed Nuri Kursunlu, Mustafa Ozmen, Ceren Bozdag, Selman Alkan, Alper Varman, Mehmet Aykut Yildirim, Tevfik Kucukkartallar, Celalettin Vatansev
Effective anticancer agents based-on two Pillar[5]arene derivatives for pancreas cancer cell lines: synthesis, apoptotic effect, caspase pathway. Investigational new drugs (2023)
Ilya Tsimafeyeu, Galina Statsenko, Liubov Vladimirova, Natalia Besova, Elena Artamonova, Grigory Raskin, Ivan Rykov, Anastasia Mochalova, Igor Utyashev, Svetlana Gorbacheva, Vasily Kazey, Evgenia Gavrilova, Nadezhda Dragun, Vladimir Moiseyenko, Sergei Tjulandin
A phase 1b study of the allosteric extracellular FGFR2 inhibitor alofanib in patients with pretreated advanced gastric cancer. Investigational new drugs (2023)
Danny N Khalil, Isabel Prieto González-Albo, Lee Rosen, Tom Lillie, Andrea Stacey, Lola Parfitt, Gerald A Soff
A tumor-selective adenoviral vector platform induces transient antiphospholipid antibodies, without increased risk of thrombosis, in phase 1 clinical studies. Investigational new drugs (2023)
James Chih-Hsin Yang, Wu-Chou Su, Chao-Hua Chiu, Her-Shyong Shiah, Kang-Yun Lee, Te-Chun Hsia, Makiko Uno, Nigel Crawford, Hiroshi Terakawa, Wen-Chi Chen, Gensuke Takayama, Ching Hsu, Ying Hong, Carline Saintilien, Joseph McGill, Gee-Chen Chang
Evaluation of combination treatment with DS-1205c, an AXL kinase inhibitor, and osimertinib in metastatic or unresectable EGFR-mutant non-small cell lung cancer: results from a multicenter, open-label phase 1 study. Investigational new drugs (2023)
Hana Dostálová, Radek Jorda, Eva Řezníčková, Vladimír Kryštof
Anticancer effect of zanubrutinib in HER2-positive breast cancer cell lines. Investigational new drugs (2023)
Zhuang Kang, Shenglan Li, Yi Lin, Yongsheng Li, Ying Mao, Jing Zhang, Ting Lei, Haidan Wang, Yangzhi Su, Yang Yang, Jingbo Qiu, Wenbin Li
A phase I dose-escalation study of SYHA1813, a VEGFR and CSF1R inhibitor, in patients with recurrent High-Grade Gliomas or Advanced Solid Tumors. Investigational new drugs (2023)
Danny N Khalil, Isabel Prieto González-Albo, Lee Rosen, Tom Lillie, Andrea Stacey, Lola Parfitt, Gerald A Soff
A tumor-selective adenoviral vector platform induces transient antiphospholipid antibodies, without increased risk of thrombosis, in phase 1 clinical studies. Investigational new drugs (2023)
Hiroya Manaka, Satoshi Igawa, Michiko Yamamoto, Akito Oguri, Hideaki Manabe, Masashi Kasajima, Seiichiro Kusuhara, Shinji Hosotani, Yoshiro Nakahara, Takashi Sato, Tomoya Fukui, Mitsufuji Hisashi, Jiichiro Sasaki, Katsuhiko Naoki
Combination carboplatin and nab-paclitaxel as a first-line treatment for advanced thymic carcinoma. Investigational new drugs (2023)
Emi Ishikawa, Yuta Yokoyama, Haruna Chishima, Hidefumi Kasai, Ouki Kuniyoshi, Motonori Kimura, Jun Hakamata, Hideo Nakada, Naoya Suehiro, Naoki Nakaya, Hideo Nakajima, Shinnosuke Ikemura, Ichiro Kawada, Hiroyuki Yasuda, Hideki Terai, Aya Jibiki, Hitoshi Kawazoe, Kenzo Soejima, Hiroshi Muramatsu, Sayo Suzuki, Tomonori Nakamura
Population Pharmacokinetics, Pharmacogenomics, and Adverse Events of Osimertinib and its Two Active Metabolites, AZ5104 and AZ7550, in Japanese Patients with Advanced Non-small Cell Lung Cancer: a Prospective Observational Study. Investigational new drugs (2023)
Alexander M Scherbakov, Svetlana K Vorontsova, Alvina I Khamidullina, Jasminka Mrdjanović, Olga E Andreeva, Fedor B Bogdanov, Diana I Salnikova, Vladimir Jurišić, Igor V Zavarzin, Valerii Z Shirinian
Novel pentacyclic derivatives and benzylidenes of the progesterone series cause anti-estrogenic and antiproliferative effects and induce apoptosis in breast cancer cells. Investigational new drugs (2023)
Alexander M Scherbakov, Svetlana K Vorontsova, Alvina I Khamidullina, Jasminka Mrdjanović, Olga E Andreeva, Fedor B Bogdanov, Diana I Salnikova, Vladimir Jurišić, Igor V Zavarzin, Valerii Z Shirinian
Novel pentacyclic derivatives and benzylidenes of the progesterone series cause anti-estrogenic and antiproliferative effects and induce apoptosis in breast cancer cells. Investigational new drugs (2023)
Siqi Shang, Yunshuo Chen, Xuejiao Yang, Ying Yang, Wenbo Wang, Yueying Wang
RNA silencing of GM-CSF in CAR-T cells reduces the secretion of multiple inflammatory cytokines. Investigational new drugs (2023)
Shintaro Takaki, Masayuki Kurosaki, Nami Mori, Keiji Tsuji, Hironori Ochi, Hiroyuki Marusawa, Shinichiro Nakamura, Toshifumi Tada, Ryoichi Narita, Yasushi Uchida, Takehiro Akahane, Masahiko Kondo, Atsunori Kusakabe, Koichiro Furuta, Haruhiko Kobashi, Hirotaka Arai, Michiko Nonogi, Takashi Tamada, Chitomi Hasebe, Chikara Ogawa, Takashi Sato, Nobuharu Tamaki, Yutaka Yasui, Kaoru Tsuchiya, Namiki Izumi
Effects on survival of the adverse event of atezolizumab plus bevacizumab for hepatocellular carcinoma: a multicenter study by the Japan Red Cross Liver Study Group. Investigational new drugs (2023)
Antonio Jimeno, Joaquina Baranda, Wade T Iams, Jong Chul Park, Monica Mita, Michael S Gordon, Matthew Taylor, Neesha Dhani, Alexis D Leal, Prakash Neupane, Cathy Eng, Oladapo Yeku, Alain Mita, Justin C Moser, Marcus Butler, Scott M Loughhead, Julia Jennings, Nathan R Miselis, Rui-Ru Ji, Nitya Nair, Martin Kornacker, Ricardo F Zwirtes, Howard Bernstein, Armon Sharei
Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ-PBMC-HPV) in HLA-A*02+ patients with HPV16+ solid tumors. Investigational new drugs (2023)
Atsushi Osoegawa, Yohei Takumi, Takafumi Hashimoto, Shotaro Nakatsuji, Mayu Hori, Mayu Sakai, Takashi Karashima, Miyuki Abe, Michiyo Miyawaki, Kenji Sugio
Cyclin-dependent kinase (CDK) 4/6 inhibition in non-small cell lung cancer with epidermal growth factor receptor (EGFR) mutations. Investigational new drugs (2023)
Linlin Hu, Ting Dou, Qiuyue Sun, Lu Tang, Mingmin Cai, Wei Qian, Huiping Wang
Effect of a moderate CYP3A inducer efavirenz on the pharmacokinetics of fuzuloparib: An open-label, fixed sequence study in Chinese healthy male subjects. Investigational new drugs (2023)
Sara Varatanovic, Tobias Maier, Sega Al-Gboore, Stefan Stoiber, Sam Augustine Kandathil, Clemens Quint, Charlotte Brennus, Gregor Heiduschka, Lorenz Kadletz-Wanke, Faris F Brkic
In vitro effects of gamma-secretase inhibition in HPV-positive and HPV-negative head and neck squamous cell carcinoma. Investigational new drugs (2023)
Mingzhen Zhou, Sihui Zhu, Chen Xu, Baorui Liu, Jie Shen
A phase Ib/II study of BLU-554, a fibroblast growth factor receptor 4 inhibitor in combination with CS1001, an anti-PD-L1, in patients with locally advanced or metastatic hepatocellular carcinoma. Investigational new drugs (2023)
Chunjiang Wang, Hanqing Zeng, Weijin Fang, Liying Song
Clinical characteristics, treatment and outcome of nivolumab-induced myasthenia gravis. Investigational new drugs (2023)
Alexander M Scherbakov, Svetlana K Vorontsova, Alvina I Khamidullina, Jasminka Mrdjanović, Olga E Andreeva, Fedor B Bogdanov, Diana I Salnikova, Vladimir Jurišić, Igor V Zavarzin, Valerii Z Shirinian
Novel pentacyclic derivatives and benzylidenes of the progesterone series cause anti-estrogenic and antiproliferative effects and induce apoptosis in breast cancer cells. Investigational new drugs (2023)
Emi Ishikawa, Yuta Yokoyama, Haruna Chishima, Hidefumi Kasai, Ouki Kuniyoshi, Motonori Kimura, Jun Hakamata, Hideo Nakada, Naoya Suehiro, Naoki Nakaya, Hideo Nakajima, Shinnosuke Ikemura, Ichiro Kawada, Hiroyuki Yasuda, Hideki Terai, Aya Jibiki, Hitoshi Kawazoe, Kenzo Soejima, Hiroshi Muramatsu, Sayo Suzuki, Tomonori Nakamura
Population Pharmacokinetics, Pharmacogenomics, and Adverse Events of Osimertinib and its Two Active Metabolites, AZ5104 and AZ7550, in Japanese Patients with Advanced Non-small Cell Lung Cancer: a Prospective Observational Study. Investigational new drugs (2023)
Alexander M Scherbakov, Svetlana K Vorontsova, Alvina I Khamidullina, Jasminka Mrdjanović, Olga E Andreeva, Fedor B Bogdanov, Diana I Salnikova, Vladimir Jurišić, Igor V Zavarzin, Valerii Z Shirinian
Novel pentacyclic derivatives and benzylidenes of the progesterone series cause anti-estrogenic and antiproliferative effects and induce apoptosis in breast cancer cells. Investigational new drugs (2023)
Gaobo Yan, Hongyan Zhang, Yan Li, Guoqiang Miao, Xiaolei Liu, Qifan Lv
Viscosalactone B, a natural LSD1 inhibitor, inhibits proliferation in vitro and in vivo against prostate cancer cells. Investigational new drugs (2023)
Alexander S Vedenkin, Sergey V Stovbun, Alexander A Bukhvostov, Dmitry V Zlenko, Ivan S Stovbun, Vladimir N Silnikov, Valentin V Fursov, Dmitry A Kuznetsov
Anti-cancer activity of ultra-short single-stranded polydeoxyribonucleotides. Investigational new drugs (2023)
Rana Vafaei, Zohreh Khaki, Malihe Salehi, Neda Jalili, Mohammad Reza Esmailinejad, Ahad Muhammadnajad, Seyed Mahdi Nassiri, Alireza Vajhi, Shima Moradi Kalbolandi, Roya Mirzaei, Leila Farahmand
Development of a MET-targeted single-chain antibody fragment as an anti-oncogene targeted therapy for breast cancer. Investigational new drugs (2023)
Siqi Shang, Yunshuo Chen, Xuejiao Yang, Ying Yang, Wenbo Wang, Yueying Wang
RNA silencing of GM-CSF in CAR-T cells reduces the secretion of multiple inflammatory cytokines. Investigational new drugs (2023)
Alexander M Scherbakov, Svetlana K Vorontsova, Alvina I Khamidullina, Jasminka Mrdjanović, Olga E Andreeva, Fedor B Bogdanov, Diana I Salnikova, Vladimir Jurišić, Igor V Zavarzin, Valerii Z Shirinian
Novel pentacyclic derivatives and benzylidenes of the progesterone series cause anti-estrogenic and antiproliferative effects and induce apoptosis in breast cancer cells. Investigational new drugs (2023)
Hiroya Manaka, Satoshi Igawa, Michiko Yamamoto, Akito Oguri, Hideaki Manabe, Masashi Kasajima, Seiichiro Kusuhara, Shinji Hosotani, Yoshiro Nakahara, Takashi Sato, Tomoya Fukui, Mitsufuji Hisashi, Jiichiro Sasaki, Katsuhiko Naoki
Combination carboplatin and nab-paclitaxel as a first-line treatment for advanced thymic carcinoma. Investigational new drugs (2023)
Markus Joerger, Thomas Hundsberger, Simon Haefliger, Roger von Moos, Andreas F Hottinger, Thomas Kaindl, Marc Engelhardt, Michalina Marszewska, Heidi Lane, Patrick Roth, Anastasios Stathis
Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a study. Investigational new drugs (2023)

volume 41, number 1, 2023

Gaobo Yan, Hongyan Zhang, Yan Li, Guoqiang Miao, Xiaolei Liu, Qifan Lv
Viscosalactone B, a natural LSD1 inhibitor, inhibits proliferation in vitro and in vivo against prostate cancer cells. Investigational new drugs 41 (1) (2023)
Mingzhen Zhou, Sihui Zhu, Chen Xu, Baorui Liu, Jie Shen
A phase Ib/II study of BLU-554, a fibroblast growth factor receptor 4 inhibitor in combination with CS1001, an anti-PD-L1, in patients with locally advanced or metastatic hepatocellular carcinoma. Investigational new drugs 41 (1) (2023)
Hiroya Manaka, Satoshi Igawa, Michiko Yamamoto, Akito Oguri, Hideaki Manabe, Masashi Kasajima, Seiichiro Kusuhara, Shinji Hosotani, Yoshiro Nakahara, Takashi Sato, Tomoya Fukui, Mitsufuji Hisashi, Jiichiro Sasaki, Katsuhiko Naoki
Combination carboplatin and nab-paclitaxel as a first-line treatment for advanced thymic carcinoma. Investigational new drugs 41 (1) (2023)
Hiroya Manaka, Satoshi Igawa, Michiko Yamamoto, Akito Oguri, Hideaki Manabe, Masashi Kasajima, Seiichiro Kusuhara, Shinji Hosotani, Yoshiro Nakahara, Takashi Sato, Tomoya Fukui, Mitsufuji Hisashi, Jiichiro Sasaki, Katsuhiko Naoki
Combination carboplatin and nab-paclitaxel as a first-line treatment for advanced thymic carcinoma. Investigational new drugs 41 (1) (2023)
Mingzhen Zhou, Sihui Zhu, Chen Xu, Baorui Liu, Jie Shen
A phase Ib/II study of BLU-554, a fibroblast growth factor receptor 4 inhibitor in combination with CS1001, an anti-PD-L1, in patients with locally advanced or metastatic hepatocellular carcinoma. Investigational new drugs 41 (1) (2023)
Emi Ishikawa, Yuta Yokoyama, Haruna Chishima, Hidefumi Kasai, Ouki Kuniyoshi, Motonori Kimura, Jun Hakamata, Hideo Nakada, Naoya Suehiro, Naoki Nakaya, Hideo Nakajima, Shinnosuke Ikemura, Ichiro Kawada, Hiroyuki Yasuda, Hideki Terai, Aya Jibiki, Hitoshi Kawazoe, Kenzo Soejima, Hiroshi Muramatsu, Sayo Suzuki, Tomonori Nakamura
Population Pharmacokinetics, Pharmacogenomics, and Adverse Events of Osimertinib and its Two Active Metabolites, AZ5104 and AZ7550, in Japanese Patients with Advanced Non-small Cell Lung Cancer: a Prospective Observational Study. Investigational new drugs 41 (1) (2023)
Alexander M Scherbakov, Svetlana K Vorontsova, Alvina I Khamidullina, Jasminka Mrdjanović, Olga E Andreeva, Fedor B Bogdanov, Diana I Salnikova, Vladimir Jurišić, Igor V Zavarzin, Valerii Z Shirinian
Novel pentacyclic derivatives and benzylidenes of the progesterone series cause anti-estrogenic and antiproliferative effects and induce apoptosis in breast cancer cells. Investigational new drugs 41 (1) (2023)
Alexander S Vedenkin, Sergey V Stovbun, Alexander A Bukhvostov, Dmitry V Zlenko, Ivan S Stovbun, Vladimir N Silnikov, Valentin V Fursov, Dmitry A Kuznetsov
Anti-cancer activity of ultra-short single-stranded polydeoxyribonucleotides. Investigational new drugs 41 (1) (2023)
Mingzhen Zhou, Sihui Zhu, Chen Xu, Baorui Liu, Jie Shen
A phase Ib/II study of BLU-554, a fibroblast growth factor receptor 4 inhibitor in combination with CS1001, an anti-PD-L1, in patients with locally advanced or metastatic hepatocellular carcinoma. Investigational new drugs 41 (1) (2023)
Alexander S Vedenkin, Sergey V Stovbun, Alexander A Bukhvostov, Dmitry V Zlenko, Ivan S Stovbun, Vladimir N Silnikov, Valentin V Fursov, Dmitry A Kuznetsov
Anti-cancer activity of ultra-short single-stranded polydeoxyribonucleotides. Investigational new drugs 41 (1) (2023)
Gaobo Yan, Hongyan Zhang, Yan Li, Guoqiang Miao, Xiaolei Liu, Qifan Lv
Viscosalactone B, a natural LSD1 inhibitor, inhibits proliferation in vitro and in vivo against prostate cancer cells. Investigational new drugs 41 (1) (2023)
Hiroya Manaka, Satoshi Igawa, Michiko Yamamoto, Akito Oguri, Hideaki Manabe, Masashi Kasajima, Seiichiro Kusuhara, Shinji Hosotani, Yoshiro Nakahara, Takashi Sato, Tomoya Fukui, Mitsufuji Hisashi, Jiichiro Sasaki, Katsuhiko Naoki
Combination carboplatin and nab-paclitaxel as a first-line treatment for advanced thymic carcinoma. Investigational new drugs 41 (1) (2023)
Gaobo Yan, Hongyan Zhang, Yan Li, Guoqiang Miao, Xiaolei Liu, Qifan Lv
Viscosalactone B, a natural LSD1 inhibitor, inhibits proliferation in vitro and in vivo against prostate cancer cells. Investigational new drugs 41 (1) (2023)
Alexander M Scherbakov, Svetlana K Vorontsova, Alvina I Khamidullina, Jasminka Mrdjanović, Olga E Andreeva, Fedor B Bogdanov, Diana I Salnikova, Vladimir Jurišić, Igor V Zavarzin, Valerii Z Shirinian
Novel pentacyclic derivatives and benzylidenes of the progesterone series cause anti-estrogenic and antiproliferative effects and induce apoptosis in breast cancer cells. Investigational new drugs 41 (1) (2023)
Emi Ishikawa, Yuta Yokoyama, Haruna Chishima, Hidefumi Kasai, Ouki Kuniyoshi, Motonori Kimura, Jun Hakamata, Hideo Nakada, Naoya Suehiro, Naoki Nakaya, Hideo Nakajima, Shinnosuke Ikemura, Ichiro Kawada, Hiroyuki Yasuda, Hideki Terai, Aya Jibiki, Hitoshi Kawazoe, Kenzo Soejima, Hiroshi Muramatsu, Sayo Suzuki, Tomonori Nakamura
Population Pharmacokinetics, Pharmacogenomics, and Adverse Events of Osimertinib and its Two Active Metabolites, AZ5104 and AZ7550, in Japanese Patients with Advanced Non-small Cell Lung Cancer: a Prospective Observational Study. Investigational new drugs 41 (1) (2023)
Emi Ishikawa, Yuta Yokoyama, Haruna Chishima, Hidefumi Kasai, Ouki Kuniyoshi, Motonori Kimura, Jun Hakamata, Hideo Nakada, Naoya Suehiro, Naoki Nakaya, Hideo Nakajima, Shinnosuke Ikemura, Ichiro Kawada, Hiroyuki Yasuda, Hideki Terai, Aya Jibiki, Hitoshi Kawazoe, Kenzo Soejima, Hiroshi Muramatsu, Sayo Suzuki, Tomonori Nakamura
Population Pharmacokinetics, Pharmacogenomics, and Adverse Events of Osimertinib and its Two Active Metabolites, AZ5104 and AZ7550, in Japanese Patients with Advanced Non-small Cell Lung Cancer: a Prospective Observational Study. Investigational new drugs 41 (1) (2023)
Emi Ishikawa, Yuta Yokoyama, Haruna Chishima, Hidefumi Kasai, Ouki Kuniyoshi, Motonori Kimura, Jun Hakamata, Hideo Nakada, Naoya Suehiro, Naoki Nakaya, Hideo Nakajima, Shinnosuke Ikemura, Ichiro Kawada, Hiroyuki Yasuda, Hideki Terai, Aya Jibiki, Hitoshi Kawazoe, Kenzo Soejima, Hiroshi Muramatsu, Sayo Suzuki, Tomonori Nakamura
Population Pharmacokinetics, Pharmacogenomics, and Adverse Events of Osimertinib and its Two Active Metabolites, AZ5104 and AZ7550, in Japanese Patients with Advanced Non-small Cell Lung Cancer: a Prospective Observational Study. Investigational new drugs 41 (1) (2023)
Emi Ishikawa, Yuta Yokoyama, Haruna Chishima, Hidefumi Kasai, Ouki Kuniyoshi, Motonori Kimura, Jun Hakamata, Hideo Nakada, Naoya Suehiro, Naoki Nakaya, Hideo Nakajima, Shinnosuke Ikemura, Ichiro Kawada, Hiroyuki Yasuda, Hideki Terai, Aya Jibiki, Hitoshi Kawazoe, Kenzo Soejima, Hiroshi Muramatsu, Sayo Suzuki, Tomonori Nakamura
Population Pharmacokinetics, Pharmacogenomics, and Adverse Events of Osimertinib and its Two Active Metabolites, AZ5104 and AZ7550, in Japanese Patients with Advanced Non-small Cell Lung Cancer: a Prospective Observational Study. Investigational new drugs 41 (1) (2023)
Gaobo Yan, Hongyan Zhang, Yan Li, Guoqiang Miao, Xiaolei Liu, Qifan Lv
Viscosalactone B, a natural LSD1 inhibitor, inhibits proliferation in vitro and in vivo against prostate cancer cells. Investigational new drugs 41 (1) (2023)
Alexander S Vedenkin, Sergey V Stovbun, Alexander A Bukhvostov, Dmitry V Zlenko, Ivan S Stovbun, Vladimir N Silnikov, Valentin V Fursov, Dmitry A Kuznetsov
Anti-cancer activity of ultra-short single-stranded polydeoxyribonucleotides. Investigational new drugs 41 (1) (2023)
Alexander M Scherbakov, Svetlana K Vorontsova, Alvina I Khamidullina, Jasminka Mrdjanović, Olga E Andreeva, Fedor B Bogdanov, Diana I Salnikova, Vladimir Jurišić, Igor V Zavarzin, Valerii Z Shirinian
Novel pentacyclic derivatives and benzylidenes of the progesterone series cause anti-estrogenic and antiproliferative effects and induce apoptosis in breast cancer cells. Investigational new drugs 41 (1) (2023)